Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Insider Sells $319,598.34 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) insider Joanne Quan sold 6,969 shares of Mirum Pharmaceuticals stock in a transaction dated Friday, January 17th. The shares were sold at an average price of $45.86, for a total value of $319,598.34. Following the completion of the transaction, the insider now directly owns 5,649 shares of the company’s stock, valued at approximately $259,063.14. This represents a 55.23 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Mirum Pharmaceuticals Trading Up 4.1 %

NASDAQ MIRM opened at $48.65 on Friday. The firm’s fifty day moving average price is $43.65 and its 200 day moving average price is $41.40. Mirum Pharmaceuticals, Inc. has a 12 month low of $23.14 and a 12 month high of $49.27. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. The company has a market capitalization of $2.34 billion, a price-to-earnings ratio of -24.08 and a beta of 0.98.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The company had revenue of $90.38 million for the quarter, compared to analyst estimates of $81.99 million. During the same quarter last year, the company posted ($0.57) earnings per share. The business’s quarterly revenue was up 89.4% compared to the same quarter last year. On average, sell-side analysts expect that Mirum Pharmaceuticals, Inc. will post -1.45 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Mirum Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MIRM. Amalgamated Bank increased its holdings in shares of Mirum Pharmaceuticals by 60.8% in the 2nd quarter. Amalgamated Bank now owns 1,357 shares of the company’s stock valued at $46,000 after acquiring an additional 513 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in Mirum Pharmaceuticals by 22.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock valued at $67,000 after purchasing an additional 318 shares during the period. R Squared Ltd acquired a new position in Mirum Pharmaceuticals in the fourth quarter valued at $69,000. Avanza Fonder AB purchased a new stake in shares of Mirum Pharmaceuticals in the fourth quarter valued at about $189,000. Finally, ProShare Advisors LLC acquired a new stake in shares of Mirum Pharmaceuticals during the second quarter worth about $213,000.

Wall Street Analysts Forecast Growth

MIRM has been the subject of a number of research reports. HC Wainwright restated a “buy” rating and issued a $66.00 price objective on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th. Citigroup upped their price objective on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Leerink Partners boosted their target price on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. Finally, Robert W. Baird lifted their price objective on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Mirum Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $57.10.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.